Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Liabilities and Shareholders Equity: 2020-2025

Historic Liabilities and Shareholders Equity for Tango Therapeutics (TNGX) over the last 5 years, with Sep 2025 value amounting to $210.1 million.

  • Tango Therapeutics' Liabilities and Shareholders Equity fell 40.37% to $210.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year decrease of 32.66%. This contributed to the annual value of $316.5 million for FY2024, which is 21.38% down from last year.
  • As of Q3 2025, Tango Therapeutics' Liabilities and Shareholders Equity stood at $210.1 million, which was down 11.67% from $237.9 million recorded in Q2 2025.
  • In the past 5 years, Tango Therapeutics' Liabilities and Shareholders Equity registered a high of $530.1 million during Q3 2021, and its lowest value of $167.5 million during Q2 2021.
  • For the 3-year period, Tango Therapeutics' Liabilities and Shareholders Equity averaged around $344.8 million, with its median value being $379.3 million (2023).
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first soared by 214.84% in 2021, then crashed by 40.37% in 2025.
  • Over the past 5 years, Tango Therapeutics' Liabilities and Shareholders Equity (Quarterly) stood at $500.2 million in 2021, then declined by 12.73% to $436.5 million in 2022, then dropped by 7.77% to $402.6 million in 2023, then fell by 21.38% to $316.5 million in 2024, then slumped by 40.37% to $210.1 million in 2025.
  • Its last three reported values are $210.1 million in Q3 2025, $237.9 million for Q2 2025, and $274.3 million during Q1 2025.